Cancer
FDA Partially Pauses Cancer Drug Trial After Patient Death
MacroGenics reports four safety events, including one fatality, in phase 2 study of experimental therapy lorigerlimab.
MacroGenics Pauses Cancer Drug Trial After Safety Issues
FDA places hold on Phase 2 study of lorigerlimab due to adverse events in enrolled patients.
MacroGenics Pauses Enrollment in LINNET Trial Due to Safety Concerns
FDA places partial clinical hold on study of lorigerlimab in gynecologic cancer
- Chloromethane Market to Reach $10.1 Billion by 2035
- Model-Based Manufacturing Technologies Market to Reach $118.6 Bn by 2036
- Anti-Dandruff Shampoos Market to Reach $15.8B by 2036
- Ischemic Hepatitis Treatment Market to Reach $14.2B by 2036
- Fusion Energy Market to Surpass USD 572.74 Billion by 2032
- Call Center Outsourcing Market to Reach $198.90B by 2032, Driven by AI and Omnichannel CX
